Logo image of BCLI

BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Fundamental Analysis

NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD

1.73  -0.07 (-3.89%)

Fundamental Rating

1

Taking everything into account, BCLI scores 1 out of 10 in our fundamental rating. BCLI was compared to 572 industry peers in the Biotechnology industry. BCLI has a bad profitability rating. Also its financial health evaluation is rather negative. BCLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BCLI has reported negative net income.
In the past year BCLI has reported a negative cash flow from operations.
In the past 5 years BCLI always reported negative net income.
In the past 5 years BCLI always reported negative operating cash flow.
BCLI Yearly Net Income VS EBIT VS OCF VS FCFBCLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

BCLI's Return On Assets of -702.62% is on the low side compared to the rest of the industry. BCLI is outperformed by 98.58% of its industry peers.
Industry RankSector Rank
ROA -702.62%
ROE N/A
ROIC N/A
ROA(3y)-259.81%
ROA(5y)-239.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCLI Yearly ROA, ROE, ROICBCLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCLI Yearly Profit, Operating, Gross MarginsBCLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCLI has less shares outstanding
Compared to 5 years ago, BCLI has less shares outstanding
BCLI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCLI Yearly Shares OutstandingBCLI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
BCLI Yearly Total Debt VS Total AssetsBCLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

BCLI has an Altman-Z score of -179.57. This is a bad value and indicates that BCLI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -179.57, BCLI is not doing good in the industry: 98.40% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -179.57
ROIC/WACCN/A
WACCN/A
BCLI Yearly LT Debt VS Equity VS FCFBCLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

BCLI has a Current Ratio of 0.05. This is a bad value and indicates that BCLI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.05, BCLI is doing worse than 99.29% of the companies in the same industry.
A Quick Ratio of 0.05 indicates that BCLI may have some problems paying its short term obligations.
BCLI has a worse Quick ratio (0.05) than 99.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
BCLI Yearly Current Assets VS Current LiabilitesBCLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

BCLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -685.58%.
EPS 1Y (TTM)-685.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-264.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCLI will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.41% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.67%
EPS Next 2Y36.07%
EPS Next 3Y23.47%
EPS Next 5Y16.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCLI Yearly Revenue VS EstimatesBCLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
BCLI Yearly EPS VS EstimatesBCLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCLI. In the last year negative earnings were reported.
Also next year BCLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCLI Price Earnings VS Forward Price EarningsBCLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCLI Per share dataBCLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

BCLI's earnings are expected to grow with 23.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.07%
EPS Next 3Y23.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (2/21/2025, 8:02:56 PM)

1.73

-0.07 (-3.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners7.35%
Inst Owner Change-99.99%
Ins Owners17.71%
Ins Owner Change32.55%
Market Cap9.86M
Analysts85
Price Target14.11 (715.61%)
Short Float %2.05%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.5%
Min EPS beat(2)-12.04%
Max EPS beat(2)13.04%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-39.41%
PT rev (3m)-39.41%
EPS NQ rev (1m)-4.11%
EPS NQ rev (3m)-4.11%
EPS NY rev (1m)-3.23%
EPS NY rev (3m)0.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS0
BVpS-1.06
TBVpS-1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -702.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-259.81%
ROA(5y)-239.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -179.57
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.02%
Cap/Depr(5y)122.11%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-685.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-264.29%
EPS Next Y75.67%
EPS Next 2Y36.07%
EPS Next 3Y23.47%
EPS Next 5Y16.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.56%
EBIT Next 3Y6.39%
EBIT Next 5Y33.99%
FCF growth 1Y44.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.84%
OCF growth 3YN/A
OCF growth 5YN/A